GLP-1 and Kidney Stones: Urolithiasis Risk and Citrate Prevention Evidence

Kidney stones are common: roughly 10% of US men and 7% of US women will form one in their lifetime (Scales 2012, European Urology^[1]). Obesity (Taylor 2005 JAMA^[2]), type 2 diabetes (Taylor 2005 Kidney International^[3], Weinberg 2014^[4]), and Roux-en-Y gastric bypass (Lieske 2015^[5]) all raise the risk — and every one of those risk factors overlaps with the GLP-1 patient population. Direct GLP-1-and-stones data is limited, but the mechanism that deserves attention is dehydration during the dose-escalation window, when nausea blunts fluid intake. Fortunately the prevention protocol is one of the best-replicated in nephrology: hydration to 2.5+ L of urine per day (Borghi 1996^[9]), potassium citrate per the AUA 2014 guideline (Pearle^[7]), normal dietary calcium with reduced sodium and animal protein (Borghi 2002 NEJM^[10]), and a 24-hour urine collection to personalize the rest. This article walks through what the evidence says and the practical protocol it implies for anyone starting Wegovy, Ozempic, Zepbound, or Mounjaro.

The honest summary

• Direct GLP-1-and-stones evidence is thin. Large pharmacoepidemiology comparisons of stone incidence on versus off GLP-1 therapy are sparse and confounded by the obesity and T2D background. The best-studied adjacent mechanism — sustained weight loss — lowers stone risk over years (Taylor 2005 JAMA^[2]).
• Dehydration during dose escalation is the near-term concern. Nausea and reduced appetite curtail water intake during weeks 4 through 16 of titration. Borghi 1996^[9] showed urine output below 2 L/day doubled 5-year stone recurrence vs urine output above 2 L.
• Bariatric surgery is the cautionary tale. Lieske 2015^[5] demonstrated Roux-en-Y gastric bypass roughly doubles incident stone risk via fat malabsorption and enteric hyperoxaluria; sleeve gastrectomy is intermediate (DeFoor 2016^[6]). GLP-1 therapy does not cause fat malabsorption, so the bariatric stone mechanism does not transfer — but the hydration discipline does.
• The prevention stack is decades old and works. Hydration to 2.5 L urine output, potassium citrate 30–60 mEq/day for recurrent calcium stone formers, normal calcium intake (1,000–1,200 mg/day from food), sodium below 2,300 mg/day, and moderate animal protein (Pearle 2014 AUA^[7], Borghi 2002^[10]).

Stone types: what is in there matters

• Calcium oxalate (~70–80%). The dominant stone type. Driven by low urine volume, high urine oxalate, low urine citrate, and high urine calcium. Citrate binds calcium in the urine and inhibits crystallization.
• Calcium phosphate (~10%). Often associated with higher urine pH and distal renal tubular acidosis.
• Uric acid (~10%). Strongly tied to insulin resistance and low urine pH — the same metabolic milieu seen in T2D and obesity. Patients with gout sit at the highest overlap; see our separate piece on GLP-1, uric acid, and allopurinol for the urate-stone subtype.
• Struvite. Infection-associated, typically with urea-splitting organisms. Less relevant to GLP-1 counseling but worth excluding in recurrent UTIs.
• Cystine. Genetic (cystinuria). Lifelong high-volume hydration and alkalinization.

Why GLP-1 patients deserve a stone conversation

Three independent risk factors stack in the typical GLP-1 patient and each one is established in primary-source epidemiology.

Obesity. Taylor 2005 JAMA^[2] prospectively followed three large US cohorts (over 240,000 participants combined) and reported that BMI above 30 increased the relative risk of incident kidney stones by roughly 30% in men and 90% in women versus a BMI of 21–23. Waist circumference and weight gain since early adulthood showed similar dose-response.

Type 2 diabetes. Taylor 2005 Kidney International^[3] reported a 30–50% higher incident stone risk in adults with T2D versus those without, across the same cohorts. Weinberg 2014 Eur Urol^[4] added a severity gradient: insulin-treated diabetes carried higher stone risk than oral-agent diabetes, consistent with an insulin-resistance and low-urine-pH mechanism. Uric acid stones are over-represented in this group.

Bariatric history. Lieske 2015 Kidney International^[5] followed a population-based cohort and showed Roux-en-Y gastric bypass roughly doubled incident kidney stone risk versus matched obese controls; sleeve gastrectomy was intermediate. The mechanism is fat malabsorption: unabsorbed fat binds dietary calcium in the gut, leaving free oxalate to be absorbed and excreted, which supersaturates the urine. DeFoor 2016^[6] showed the urinary biochemistry shifts (rising urinary oxalate, falling citrate) appear within months of surgery in adolescents.

GLP-1 therapy does not produce fat malabsorption, so the bariatric hyperoxaluria mechanism does not transfer. But the GLP-1 patient population overlaps heavily with patients who already have a bariatric history — see our piece on GLP-1 as a bridge to or from bariatric surgery for the decision framework — and those patients carry the bariatric stone risk forward regardless of what is started next.

The dehydration window: weeks 4–16 of titration

Borghi 1996^[9] randomized 199 first-time calcium stone formers to high-fluid intake (target urine output above 2 L/day) versus usual intake and followed them for 5 years. Recurrence was 12% in the high-fluid arm versus 27% in the usual-intake arm — an absolute risk reduction of 15 percentage points from hydration alone. The mean urine volume needed for that protection was 2.5 L/day, which translates to roughly 80–100 oz of total fluid intake for most adults.

That target is exactly the one a GLP-1 patient is most likely to miss during dose escalation. Nausea, early satiety, and the appetite drop that makes the medication work also depress drink-driven fluid intake. Our companion piece on the first 30 days on a GLP-1 walks through the hydration cadence that holds up under nausea: electrolyte-containing fluids in small frequent volumes, broth, herbal teas, and structured reminders rather than relying on thirst.

What the AUA guideline actually says

Pearle 2014 J Urol^[7] is the AUA medical-management guideline for kidney stone disease and remains the operative US standard. The recommendations a GLP-1 patient with prior stones should anchor to are:

• 24-hour urine collection after first stone in high-risk patients and after second stone in all patients. Measure volume, calcium, oxalate, citrate, uric acid, sodium, magnesium, phosphate, and pH.
• Fluid intake sufficient to achieve a urine volume of at least 2.5 L/day — the Borghi 1996^[9] target.
• Limit sodium intake to less than 2,300 mg/day for patients with high urinary calcium.
• Maintain normal dietary calcium (1,000–1,200 mg/day from food) — Curhan 1993 NEJM^[8] showed higher dietary calcium was associated with lower stone risk because food calcium binds oxalate in the gut. Calcium supplements do not show the same protective effect and may slightly raise risk; take them with meals if used at all.
• Moderate non-dairy animal protein for uric acid and calcium stone formers.
• Reduce dietary oxalate (spinach, rhubarb, beets, almonds, sweet potatoes, dark chocolate) for documented hyperoxaluria.
• Potassium citrate 30–60 mEq/day (Urocit-K is the common brand) for recurrent calcium stone formers with hypocitraturia or persistent disease despite conservative measures.

Borghi 2002 NEJM^[10] tested the package: a diet with normal calcium, reduced sodium, and reduced animal protein versus a low-calcium diet in recurrent hypercalciuric stone formers. After 5 years, the normal-calcium / low-sodium / low-protein diet had a relative risk of recurrence of 0.49 versus the low-calcium control — a 51% reduction. Adding hydration on top of that yields the compounded prevention typically credited to the AUA package.

SGLT2 inhibitors for context

Paik 2024 JAMA Internal Medicine^[11] used a target trial emulation in adults with T2D and reported that SGLT2 inhibitors were associated with about 30% lower nephrolithiasis risk versus DPP-4 inhibitors and roughly 30% lower versus GLP-1 receptor agonists. The proposed mechanism is the osmotic diuresis SGLT2 inhibitors produce, which increases urine volume — effectively a pharmacological version of the Borghi hydration intervention. GLP-1 agents do not share that diuretic effect, so any stone-protection from a GLP-1 is downstream of weight loss and metabolic improvement, not an acute urinary-volume effect.

The clinical read-through is not that SGLT2 should replace GLP-1 in stone formers — the indications and weight-loss magnitudes are different — but that in a T2D patient with a meaningful stone history, layering an SGLT2 inhibitor on top of a GLP-1 may carry a stone-prevention bonus worth discussing with the prescribing clinician. The FLOW trial of semaglutide in CKD provides separate evidence that GLP-1 therapy itself protects glomerular filtration in T2D-CKD, so the kidney story is broader than stones.

Magnitude: annual stone recurrence rate per 100 patients

The practical protocol

1. Hydration: 80–100 oz/day, target urine output 2.5 L+. Use a marked bottle. During escalation weeks, add an electrolyte mix to small frequent sips. Pale-yellow urine is the bedside check.
2. 24-hour urine collection at baseline for any patient with a prior stone, and repeat at 6 months on a stable GLP-1 dose. Measure volume, calcium, oxalate, citrate, uric acid, sodium, magnesium, phosphate, and pH.
3. Potassium citrate 30–60 mEq/day (Urocit-K or generic) for recurrent calcium stone formers with documented hypocitraturia. Cost is typically $30–60/month and is covered by most insurance plans. Titrate to a urine citrate target above 320 mg/day.
4. Sodium below 2,300 mg/day for patients with hypercalciuria. Cooking from scratch beats label reading.
5. Normal calcium intake (1,000–1,200 mg/day) from food. Yogurt, milk, cheese, fortified plant milks. Take any calcium supplement with meals to bind dietary oxalate. Pair with our piece on iron and calcium absorption on a GLP-1 for the multi-mineral coordination.
6. Reduce oxalate-rich foods only if 24-hour urine shows hyperoxaluria. Spinach, rhubarb, beets, almonds, sweet potato, and dark chocolate are the heavy contributors.
7. Moderate animal protein to roughly 0.8–1.0 g/kg/day for uric acid stone formers; higher targets are fine for calcium oxalate formers without hyperuricosuria.
8. Urology referral for any patient with a symptomatic stone on therapy, two or more 24-hour urine abnormalities not responding to first-line measures, or imaging showing stones above 5 mm. Lithotripsy, ureteroscopy, and percutaneous nephrolithotomy are standard.

Special situations

Pregnancy. GLP-1 receptor agonists are contraindicated during pregnancy regardless of stone status; pregnancy itself raises stone risk via altered calcium metabolism, and management is conservative with hydration and ureteric stenting if needed.

Loop diuretics. Furosemide and other loop diuretics increase urinary calcium excretion and can worsen hypercalciuria; thiazides do the opposite and are sometimes added for stone prevention. Coordinate with the prescribing clinician if a GLP-1 patient is on either.

Pediatric and adolescent patients. DeFoor 2016^[6] documented hyperoxaluria within 12 months of bariatric surgery in adolescents. Pediatric GLP-1 use is limited but expanding; the same hydration discipline applies.

Related research and tools

• GLP-1 and the FLOW trial in chronic kidney disease — the eGFR and albuminuria evidence in T2D-CKD
• GLP-1 as a bridge to or from bariatric surgery — the decision framework when stone risk is on the table
• GLP-1, uric acid, and allopurinol — the urate-stone overlap and gout co-management
• The first 30 days on a GLP-1 — hydration cadence during the nausea window
• Iron deficiency and ferritin on a GLP-1 — calcium timing and absorption coordination
• GLP-1 side-effect timeline — when nausea peaks and hydration most matters
• Hydration calculator — daily fluid target by weight and activity